Amgen's Q4 Preview: Wall Street's Mixed Signals on the Biotech Giant
As Amgen prepares to report earnings, analysts are divided on the stock's trajectory. While strategic acquisitions and a solid track record fuel optimism, looming competitive pressures and a key pipeline wait temper expectations.